Media

Aprea Therapeutics Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML

Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021

BONESUPPORT HOLDING AB (PUBL) – PUBLISHES Q2 2021 INTERIM REPORT

Strongbridge Biopharma plc Announces Publication of Long-term Efficacy and Safety Results for KEVEYIS® (dichlorphenamide) for the Treatment of Primary Periodic Paralysis in Muscle & Nerve

BONESUPPORT HOLDING AB (publ) – Interim Report Q2 2021 Invitation to conference call and webcast

Updated results from phase 3 OCEAN study shows melflufen met primary endpoint of superior PFS – Overall Survival data lead to partial clinical hold

Adcendo Appoints Michael Pehl as Chief Executive Officer

Nordic Nanovector Appoints Malene Brondberg as Interim Chief Executive Officer

Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors